Subscribe to RSS
Download PDF
DOI: 10.1055/a-2751-8379
Profiling Initial Thrombin Generation in Cardiovascular Disease Using a High Sensitivity Coagulation Assay
Authors
Funding Information This study was supported by a Grant-in-Aid for Scientific Research (#22K08209, #25K02647) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; a Grant for Precursory Research for Embryonic Science and Technology (PRESTO) from the Japan Science and Technology Agency (JST); and by the Japan Agency for Medical Research and Development (AMED) (# JP24he2622006).
Abstract
Background
Initial thrombin (FIIa) generation is a critical trigger for the amplification and propagation phases of coagulation, driven by two distinct pathways: the tissue factor (TF)-driven and the FVIIIa/FIXa-dependent pathways. However, the clinical utility of measuring initial thrombin generation (ITG) as a marker of thrombogenicity or as a tool to monitor the efficacy of oral anti-FXa therapy remains uncertain.
Methods
ITG driven by TF and the FVIIIa/FIXa complex was first measured in plasma samples from healthy adults (n = 40). This was followed by an analysis of ITG profiles in 771 consecutive patients with cardiovascular diseases to evaluate the effects of anticoagulant therapy and clinical characteristics.
Results
Of the 771 patients studied, 169 were receiving direct oral anticoagulants (DOACs). DOAC treatment significantly suppressed thrombin generation via both TF-driven and FVIIIa/FIXa-dependent pathways. Receiver operating characteristic (ROC) analysis confirmed the strong discriminatory power of both pathways for detecting DOAC use (FVIIIa/FIXa: AUC 0.863, 95% CI: 0.826–0.900; TF: AUC 0.887, 95% CI: 0.856–0.917; both p values < 0.0001). Among patients not on anticoagulants, logistic regression revealed that dialysis was associated with reduced thrombin generation through both pathways. Furthermore, chronic kidney disease and active cancer were specifically associated with diminished TF-driven thrombin generation.
Conclusion
The ITG potentials driven by TF- and FVIIIa/FIXa-dependent pathways represent promising biomarkers for evaluating anticoagulant efficacy. Moreover, the distinct influence of pathological conditions on each pathway underscores the need to account for specific disease contexts when assessing coagulation potential.
Keywords
thrombin formation - tissue factor - factor VIII - factor IX - direct oral anticoagulants - DOACsPublication History
Received: 09 July 2025
Accepted after revision: 19 November 2025
Accepted Manuscript online:
21 November 2025
Article published online:
08 December 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Ajjan RA, Kietsiriroje N, Badimon L. et al. Antithrombotic therapy in diabetes: which, when, and for how long?. Eur Heart J 2021; 42 (23) 2235-2259
- 2 Martens KL, Dekker SE, Crowe M, DeLoughery TG, Shatzel JJ. Challenging clinical scenarios for therapeutic anticoagulation: a practical approach. Thromb Res 2022; 218: 72-82
- 3 Masunaga N, Ishii M, Oka K. et al; Fushimi AF Registry Investigators. 10-year trends of antithrombotic therapy status and clinical outcomes in patients with atrial fibrillation and renal dysfunction—the Fushimi AF Registry. Circ J 2025; 89 (02) 174-183
- 4 Ruf W. Roles of factor Xa beyond coagulation. J Thromb Thrombolysis 2021; 52 (02) 391-396
- 5 Kitahara H, Yamazaki T, Hiraga T. et al. Impact of underdosing of direct oral anticoagulants on clinical outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention. Circ J 2025; 89 (02) 195-203
- 6 Yasuda S, Kaikita K, Akao M. et al; AFIRE Investigators. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019; 381 (12) 1103-1113
- 7 Rodriguez F, Harrington RA. Management of antithrombotic therapy after acute coronary syndromes. N Engl J Med 2021; 384 (05) 452-460
- 8 Shaw JR, Castellucci LA, Siegal D, Carrier M. DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays—a review of the literature. J Thromb Haemost 2023; 21 (03) 433-452
- 9 Negrier C, Shima M, Hoffman M. The central role of thrombin in bleeding disorders. Blood Rev 2019; 38: 100582
- 10 Sidonio Jr RF, Hoffman M, Kenet G, Dargaud Y. Thrombin generation and implications for hemophilia therapies: a narrative review. Res Pract Thromb Haemost 2022; 7 (01) 100018
- 11 Hoffman M, Monroe DM. Impact of non-vitamin K antagonist oral anticoagulants from a basic science perspective. Arterioscler Thromb Vasc Biol 2017; 37 (10) 1812-1818
- 12 Kamikubo Y, Mendolicchio GL, Zampolli A. et al. Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex. Blood 2017; 130 (14) 1661-1670
- 13 Kamikubo Y, Nagaya S, Inoue R. et al. Tissue factor pathway-driven initial thrombin generation is associated with hypercoagulability in obesity. Thromb Haemost 2025; . Epub ahead of print
- 14 Bhandari M, Pradhan A, Vishwakarma P. et al. Direct oral anticoagulant use in older adults with atrial fibrillation: challenges and solutions. Eur Cardiol 2025; 20: e03
- 15 Hayes KN, Zhang T, Kim DH. et al. Benefits and harms of standard versus reduced-dose direct oral anticoagulant therapy for older adults with multiple morbidities and atrial fibrillation. J Am Heart Assoc 2023; 12 (21) e029865
- 16 Edwina AE, Dia N, Dreesen E. et al. Insights into the pharmacokinetics and pharmacodynamics of direct oral anticoagulants in older adults with atrial fibrillation: a structured narrative review. Clin Pharmacokinet 2023; 62 (03) 351-373
- 17 Cabral KP, Ansell J. Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation. Nat Rev Cardiol 2012; 9 (07) 385-391
- 18 Ocak G, Noordzij M, Rookmaaker MB. et al. Mortality due to bleeding, myocardial infarction and stroke in dialysis patients. J Thromb Haemost 2018; 16 (10) 1953-1963
- 19 Jeong JC, Kim J-E, Ryu JW, Joo KW, Kim HK. Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: hypercoagulability in patients with vascular access thrombosis. Thromb Res 2013; 132 (05) 604-609
- 20 Lim HY, Lui B, Tacey M. et al. Global coagulation assays in patients with chronic kidney disease and their role in predicting thrombotic risk. Thromb Res 2023; 226: 127-135
- 21 Wan T, Song J, Zhu D. Cancer-associated venous thromboembolism: a comprehensive review. Thromb J 2025; 23 (01) 35
- 22 Nakano Y, Adachi S, Imai R. et al. Mortality, recurrent thromboembolism and major bleeding in cancer-associated and non-cancer pulmonary embolism patients treated with direct oral anticoagulants. Circ J 2024; 88 (02) 243-250
- 23 Koizume S, Miyagi Y. Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications. Br J Cancer 2022; 127 (12) 2099-2107
- 24 Sletten M, Skogstrøm KB, Lind SM. et al. Elevated TFPI is a prognostic factor in hepatocellular carcinoma: putative role of miR-7-5p and miR-1236-3p. Thromb Res 2024; 241: 109073
- 25 Abu Saadeh F, Norris L, O'Toole S. et al. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer—relationship with venous thrombosis risk. Thromb Res 2013; 132 (05) 627-634
- 26 Englisch C, Moik F, Thaler J. et al. Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer. Hamostaseologie 2023; 43: S23-S23
- 27 Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 1998; 102 (04) 889-895
- 28 Wallén NH, Ladjevardi M. Influence of low- and high-dose aspirin treatment on thrombin generation in whole blood. Thromb Res 1998; 92 (04) 189-194